An experimental NNRTI, RDEA806, appeared to have strong antiviral activity and a favourable safety profile in a Phase II study presented at IAS 2008. HIV-positive patients, starting treatment for the first time, who took the NNRTI as monotherapy were reported to have a high barrier to drug resistance. Further studies involving HIV-negative subjects showed that RDEA806 was well tolerated at single doses up to 800mg, as well as multiple doses up to 1000 mg per day for two weeks. No evidence of central nervous system side-effects or rash were seen in these studies. The presenter Dr Graeme Moyle concluded by saying that, in these early studies, RDEA806 was “well tolerated with antiviral effect across all doses.”
Moyle G, et. Al. Antiviral activity of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor, in treatment of naive HIV patients. 17th International AIDS Conference, Mexico City. Abstract THAB0402, 2008.
This article was first published in September 2008.
While the content of this article was checked for accuracy at the time of publication, NAPWA recommends checking to determine whether the information is the most up-to-date available, especially when making decisions which may affect your health.
More stories from this issue.
This article contains medical information. NAPWA makes every reasonable effort to ensure the information on this website is accurate, reliable and up-to-date, including obtaining technical reviews by medically-qualified reviewers, however the authors of information on this website are not qualified to give medical advice, except where explicitly stated.
The content of this website is intended to support, not replace, the relationship between people living with HIV/AIDS and their medical advisers, and is not intended as a substitute for medical advice.
Posted online: 24 September 2008.
Last updated: 24 September 2008.
More stories about: